Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674410 | 1.00 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL12640446 | 0.84 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL19248162 | 0.81 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL4378537 | 0.81 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL788804 | 0.81 | HSD11B1 (0.68) | HSD11B1 | |
| SCHEMBL4392304 | 0.81 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL13634947 | 0.80 | HSD11B1 (0.67) | HSD11B1 | |
| SCHEMBL23815240 | 0.79 | HSD11B1 (0.83) | HSD11B1 | |
| SCHEMBL4377098 | 0.79 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL13635045 | 0.79 | HSD11B1 (1.00) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119104707-A | Method for in-vitro evaluation of cosmetic raw materials and nerve beautifying effect of finished product | 广东迪美新材料科技有限公司 | 2024-12-10 | — | — | CN | claimed |
| WO-2021180643-A1 | HSD11B1 INHIBITORS FOR USE IN IMMUNOTHERAPY AND USES THEREOF | UNIVERSITE DE GENEVE (CH) | 2021-09-16 | — | — | WO | claimed |
| EP-3878446-A1 | HSD11B1 INHIBITORS FOR USE IN IMMUNOTHERAPY AND USES THEREOF | UNIVERSITE DE GENEVE (CH) | 2021-09-15 | — | — | EP | claimed |
| US-20260137658-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137660-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250319072-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12329745-B2 | Methods and compositions for treating glucocorticoid excess | SPARROW PHARMACEUTICALS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025068686-A1 | TREATMENT FOR BATTEN DISEASE | THE ROYAL VETERINARY COLLEGE (GB) | 2025-04-03 | — | — | WO | disclosed |
| US-20170232007-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | SANNA PIETRO PAOLO (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016164413-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| EP-1893609-B1 | N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES | PFIZER (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7462634-B2 | N-(pyridin-2-yl)-sulfonamide derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1893609-A1 | N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070072914-A1 | N-(pyridin-2-yl)-sulfonamide derivatives | AGOURON PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2006134467-A1 | N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319072-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885 |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, SHBG | HSD11B1 4/4885 |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C2, NR3C1, MC2R | HSD11B1 4/4885 |
| US-12329745-B2 | Methods and compositions for treating glucocorticoid excess | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885 |
| US-20170232007-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | HSD3B1, HSD11B1, HSD3B2 | HSD11B1 2/4885 |
| US-20260137660-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, SHBG | HSD11B1 4/4885 |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C2, NR3C1, MC2R | HSD11B1 4/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885 |
| US-20260137658-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, NR5A1 | HSD11B1 5/4885 |
| US-20070072914-A1 | N-(pyridin-2-yl)-sulfonamide derivatives | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.